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BLOOD GROUP O AND RISK OF INFECTION WITH VIBRIO CHOLERAE 
DEMA A. ALODAINI 
 
ABSTRACT 
 Cholera is an acute diarrheal illness burdening several developing countries 
caused by toxigenic Vibrio cholerae, where endemics maintain a seasonal pattern and 
occur more than once a year. Cholera is endemic in certain regions of Africa and South 
America, and southern Asia, where outbreaks are associated with poor	hygiene and 
sanitary conditions.  Every year, 3–5 million cases of cholera are diagnosed, and it causes 
more than 100,000 deaths worldwide. Cholera toxin is secreted by the V. cholerae 
bacteria and causes extreme secretory diarrhea, most commonly in poor hygiene 
environment. Watery diarrhea, vomiting, and abdominal cramps characterize the illness 
and approximately 5–10% of patients die of severe fluid loss if left untreated. The 
structure and function of the cholera toxin, its subunits, receptor, and impact on 
hyperactivation of cyclic adenosine monophosphate (cAMP) were sufficiently described 
in the 1970s. These findings fit with epidemiologic observations, which determined that 
the cholera toxin must first enter intestinal cells by binding to monosialoganglioside 
(GM1) on the host’s epithelial surface. 
The correlation between increase risk of V. cholerae infection and individuals 
with a particular ABO blood group type is unclear because of the scarce information and 
few studies conducted. Thus, this study reviews published research articles to better 
		 v 
understanding the association between the blood group O and susceptibility to developing 
severe cholera symptoms.  
Several large studies have recorded an association between ABO blood groups 
and different infectious agents). Anthropological surveys suggest that the racial and 
geographic distribution of human blood types reflects tendencies towards specific 
erythrocyte types susceptible to infectious disease, such as cholera and malaria. 
Experimentally, the V. cholerae toxin has been extensively used as an experimental 
adjuvant, and its association with ABO groups is of practical importance for the 
development of an oral cholera vaccination. The results of previous studies provided 
strong evidence that individuals with blood type O are more vulnerable than other 
persons to severe cholera symptoms, even though the biologic basis for this association 
remains unknown. 
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INTRODUCTION 
 
1. VIBRIO CHOLERAE  
1.1 Vibrio Cholerae History and Discovery 
              During London’s Vibrio Cholerae (V. cholerae) epidemic in 1854, a scientist 
named John Snow demonstrated that all cholera cases in London could be traced to a 
single well. He believed this well to be the source of the epidemic, making this one of the 
earliest epidemiological studies (1). V. cholerae was officially described in 1854 by 
Picini, and Robert Koch, who collected a pure sample from Egyptian stool 30 years later, 
in 1883. In Calcutta in 1959, Dutta and colleagues used infant rabbits to study the 
production of diarrhea by a crude protein isolate from a V. cholerae culture filtrate. They 
showed how a cell-free culture filtrate could cause massive bacterial accumulation, 
forming what is known as rice-water fluid in the ligated ileal loops of an adult rabbit. 
 
The Vibrio genus of bacteria is pathogenic to humans and V. cholerae is the most 
widespread among all human pathogenic species. It contains a wide variety of biotypes, 
colonization factors, antibiotic resistance, receiving and transferring genes for toxin, 
capsular polysaccharides that help in chlorine resistance, and unique antigens on the 
bacteria’s surface (1). V. cholerae (family: Vibrionaceae, genus: Vibrio) is a facultative 
anaerobic, highly motile, gram-negative bacterium with curved or comma-shaped rods 
and a single polar flagellum. It is primarily found in undercooked seafood and untreated 
seawater, where the bacteria freely multiply (Figure 1) (2). 
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Figure 1. V. cholerae cell morphology imaged using an electron micrograph. The curve-shaped 
single cell is visible with a central polar flagellum (12). 
  
1.2 Nomenclature  
In the past, gram-negative, curved and rod-shaped bacteria that possess a polar 
flagellum were classified as bacteria of the Vibrio genus. In the mid-1960s, new criteria 
was developed to identify Vibrio genus taxonomy by the International Subcommittee on 
the Taxonomy of Vibrios, which excluded many species previously classified as Vibrio. 
Taxonomic studies used biochemical characteristics to separate true species of Vibrio 
from closely related genera, such as Aeromona and Plesiomonas (3).  
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1.3 Most Common Pathogenic strain of Vibrio 
 
The Vibrio genus contains species that are both pathogenic and non-pathogenic to 
humans, and currently contains 76 species that have been involved in human infections. 
The most common pathogenic species are V. cholerae, V. parahaemolyticus, and V. 
vulnificus (Table 1). V. cholerae and V. parahaemolyticus are causative agents for 
diarrheal illness, while V. vulnificus infection can vary from self-limiting gastroenteritis 
to serious soft tissue necrotization. V. mimicus excretes cholera toxin (CT), resulting in 
the development of V. cholerae-like symptoms, and V. furnissii usually causes 
gastroenteritis, skin lesions, and septicemia (3).  
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Table 1: Most Significant Pathogenic Vibrio Species in Humans 
 
++, Usually with clinical presentation, +, neither uncommon nor most normal clinical presentation, (+) rare. 
a Data illustrate Vibrio infections reported to the Centers of Disease Control (CDC) in the US (1999). 
b Data incorporate four cases related with remote travel. 
c The 31 announced cases are from a gathering of 75 cases for which information were accessible (2). 
 
 
1.4 Epidemiology of V. cholerae Infections 
The V. cholerae O1 serotype is the most common most serotype worldwide, 
contributing to significant mortality rates in developing countries (Figure 2). Serotype O1 
is responsible for major pandemics, whereas serotype O139 causes a clinically similar 
disease, epidemics, and minor pandemics. The bacteria are usually associated with 
marine shellfish, algae, plankton, and chitinous of brackish estuaries and coastal salt 
water (2–3% NaCl), including areas along the coast of the United States (US). 
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Aggregates of bacteria surrounded by a protective biofilm prevents chlorine and other 
disinfectants from sanitizing such water.  
 
V. cholerae epidemiology includes (i) a high degree of case clustering associated 
with location and season, (ii) infection rates in endemic areas that are higher among 
children aged 1–5 years than in adults, (iii) increasing rates of antibiotic resistance, (iv) 
clonal differing qualities of epidemic strains, and (v) increased awareness and protection 
against the disease (4). During the last century, cholera cases and deaths have steadily 
decreased due to improved sanitation and hygiene measures. During the summer season, 
minor outbreaks occur in afflicted developing countries as a consequence of 
overcrowding, poor living conditions, and insufficient clean drinking water. 
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Figure 2. The number of cholera cases between 1989 and 2009 worldwide. Cholera cases 
reached 44,083 in 1989 as reported by the World Health Organization (35,606 cases were in 
Africa and 8,477 cases were in Asia). In 1990, 48,403 cases were reported worldwide. In 1991, 
the disease appeared in Latin America (Peru) for the first time in 100 years, with 75,000 cases 
and 6,500 deaths, which increased until 1993. In 1994, a cholera outbreak in a Rwandan refugee 
camp near Goma, Zairw caused tens of thousands of deaths within a month. The 1995–1997 
outbreak resulted in 19,810 cases, but in 1996, Senegal reported the largest cholera outbreak 
among all African countries: 16,107 cases with 765 deaths. From 1998–2007, the number of 
cases was 322,532 in various African countries, and from 2008–2009, an estimated 4,200 people 
died in Zimbabwe (20). 
 
1.4.1 V. cholerae pandemics 
The first pandemic emerged in the Indian subcontinent (the Ganges delta) and 
extended to other continents over many years. The second pandemic occurred during the 
1830s in the British Isles, which was fully described by the epidemiologist John Snow. 
Canada was also affected during the second pandemic via ships from Ireland carrying 
infected immigrants. Between 1847 and 1854, the third and fourth pandemics took place 
in the United State, especially in cities and town along the Mississippi, Ohio, and 
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Missouri rivers. South America was affected during the fifth pandemic, with high 
mortality rates in Argentina, Peru, and Chile, at which time, it also spread throughout 
Germany, where 8,600 people died and the residents held the government responsible for 
the tragedy (5). In 1883, Robert Koch was able to isolate samples from the rice-water 
stool of infected patients in Egypt. The sixth pandemic started in India, where it killed 
more than 800,000 people and moved across the Balkan peninsula, the Middle East, 
North Africa, and Eastern Europe between 1899 and 1923.  
 
The seventh cholera pandemic was a major outbreak that occurred from 1961 to 
the 1970s and is still ongoing (6). It began on the Indonesia Island of Sulawesi, spread to 
further islands, including Java, Borneo, and Sarawak, and after that to the Philippines 
before reaching Bangladesh by 1963. The pandemic causative agent was V. cholerae O1 
of El Tor biotype, which caused 155,000 reported cases of cholera worldwide in 1971. 
By 1991, the number of cases reached 570,000 with the help of modern transportation, 
migration, and inadequate healthcare infrastructure (7). The World Health Organization 
estimated that during 1991, reported cases reached 750,000 with a mortality rate of 50% 
(6,500 deaths) in the Americas, while 12,000 died in poverty-stricken Rwandan refugees 
camps. The seventh pandemic keeps on creating occasional outbreaks in nations, 
particularly India and Bangladesh (Figure 3). The mortality rates significantly dropped 
when governments began to take more serious action against the disease through modern 
curative and preventive measures, which decreased the death rate to 3% by 1992 (8).  
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In late December 1992 in Bangladesh and India, the eighth pandemic started. All 
reported cases had similar cholera-like symptoms, and the causative agent was 
determined to be the V. cholerae non-O1 strain in 40–50% of the cases, which was later 
serogrouped as the O139 strain (9). By March 1993, over 100,000 cases and 1,400 deaths 
were reported in India, Pakistan, Nepal, and Bangladesh. Infected immigrants imported 
the disease to the US and Europe, but it remains confined to Asian countries (10). 
 
Figure 3. Locations of the seven cholera pandemics. The first pandemic remained 
predominantly in Asia, starting in Indonesia. The second pandemic also started in Asia and 
moved to North America. The third and fourth pandemics began in Asian countries and moved 
to towns the Mississippi River. The fifth pandemic affected South America and reached 
Germany. The sixth pandemic started in India and moved across the Balkan Peninsula, Middle 
East, North Africa, and Eastern Europe. The seventh pandemic continues in India and 
Bangladesh (41). 
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1.5 Toxigenic Serogroups 
                 Surface antigens of Vibrio species are used to differentiate them, and 
variations in sugar structure on the heat-stable surface somatic O antigen allow 
serological classification of V. cholerae (Figure 4). There are 206 O serogroups divided 
into O1 and non-O1 serogroups based on agglutination with the O antiserum (4). The O1 
serogroup exists as two biotypes: El Tor and classical. For further differentiation, 
biotypes have three serotypes (two major and one minor) that express different antigenic 
factors. The first major serotype is Ogawa, which has strains that express the A and B 
antigens and a trace amount of the C antigen. The second major serotype is Inaba, which 
expresses the A and C antigens. A minor serotype is Hikojima, which expresses all three 
(A, B, and C) antigens but is unstable and not as common as the two major serotypes. V. 
cholerae has non-pathogenic stains that generally do not produce cholera toxins and do 
not lead to epidemics, but in 1993, a new epidemic in Bangladesh and India was the 
result of a cholera-like disease referred to it as V. cholerae non-O1 because it did not 
agglutinate with the O1 antiserum. After further examination, this bacteria did not belong 
to any of the O serogroups, but rather to another and never described V. cholerae 
serotype, which was named the O139 Bengal serogroup (11).  
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Figure 4. V. cholerae serological classification begins with three serogroups: V. cholerae O1, V. 
cholerae Bengal O139, and V. cholerae non-O1 non-O139. It has two biotypes (classical and El Tor), 
which have three serotypes: Ogawa, Inaba, and Hikojima. The Ogawa serotype presents A and B 
antigens, the Inaba presents A and C antigens, and the Hikojima present the A, B, and C antigens. 	
1.6 Genome Structure 
The genomic structure of V. cholerae consists of two circular chromosomes. The 
first large chromosome has 2,961,149 base pairs with 2,770 open reading frames (ORF) 
and carries main genes for toxicity, regulation, and vital cell functions, for example, 
translation and transcription. The second smaller chromosome is not similar to plasmid, 
because it contains essential genes, such as housekeeping genes that included bacterial 
metabolism, heat-shock proteins, and ribosomal-RNA genes (Figure 5). It shapes 40% of 
the complete genome. Unlike plasmids, the two chromosomes are not self-transmissible. 
A viral genome with pathogenic genomic islands is responsible for the bacteria’s 
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pathogenicity, which becomes integrated into its genome and lysogenized with phage 
DNA and change its natural state (12). 
 
 
Figure 5. V. cholerae genome structure consists of two circular chromosomes. The first large 
chromosome (at the bottom) has 2,961,149 base pairs with 2,770 ORFs and carries the main 
genes for toxicity, regulation, and critical cell functions, such as translation and transcription. 
The second smaller chromosome (at the top) is distinct from the plasmid, because it contains 
essential housekeeping genes, including bacterial metabolism, heat-shock proteins, and 
ribosomal-RNA genes (9). 
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1.7 V. Cholerae Toxin and Virulence Factors  
V. cholerae toxin (CTX) is a phage-encoded A-B toxin, which belongs to the AB5 
toxins family, and it is a heteromeric enzyme of one toxigenic active catalytic A (CTA) 
subunit anchored to a second adhesive B subunit (CTB); Figure 6). The genes encoding 
the cholera toxin found on the CTX genetic element: a 7–9.7 kb segment of the DNA 
present on the chromosome of the toxigenic strains (usually in multiple tandemly arrayed 
copies) but missing in nontoxigenic species (13). The DNA of the CTC may have 
CTXphi (CTXφ), a filamentous bacteriophage either integrated as a part of the V. 
cholerae genome or present extra-chromosomally. It also carries at least six genes 
referred to it as virulence cassette, including CTX-AB (encodes the A and B subunit), zot 
(encodes the zonula occludens toxin), ace (encodes the accessory cholera enterotoxin), 
cep (encodes the core-encoded pilin), and orfU (encodes a product of unknown function) 
(4). The five B subunits form a ring and is responsible for attaching to the receptors of the 
small intestine’s epithelial cells, while the A subunit produces toxic effects. In vivo, the 
CTA subunit is hydrolyzed by enzymes to CTA1 and CTA2. CTA1 is responsible for the 
cholera disease, whereas CTA2 acts as a bonder to the CTB subunit. When CTB 
(monosialoganglioside (GM1)-binding pentameric) binds to GM1 on intestinal cells, it 
promotes the absorption of cholera toxin through retrograde endocytosis from the Golgi 
apparatus to the endoplasmic reticulum (14). This requires two coordinating regulatory 
factors for complete virulence: the cholera toxin (enterotoxin) and toxin-coregulated pilus 
(TCP), which are surface organelles essential for intestinal colonization. The CTX 
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structural genes are encoded by a filamentous bacteriophage, CTX (Phi), that uses TCP 
as its receptor. Different types of proteases (V. cholerae HA/protease) are produced to 
facilitate activation of cholera toxin and other factors, such as fimbriae. The toxR gene 
encodes the ToxR protein to stimulate the regulatory cascade in Vibrios species that is 
responsible for controlling more than 17 virulence genes, the CTX-AB gene being one of 
these (15). 
 
Figure 6: The tertiary structure of the cholera toxin is a subunit composed of the toxigenic A1 
peptide and A2 peptide (bonder to B subunit). A subunit is anchored with five B subunits in the 
center of the ring, which are bound to the GM1 receptors on the host’s intestinal cell 
membranes via KDEL motif (15). 	  
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2. CHOLERA 
2.1 Disease Description And Clinical Symptoms 
Since antiquity, cholera has referred to any type to diarrhea or dysentery, 
originating from the Greek word cholē, meaning bile. In American medical records 
during the 19th century, three types of cholera were reported: cholera infantum, cholera 
morbus (summer cholera, which occurred from July to September), and cholera Asiatic 
(another name for V. cholerae) (17). Cholera infantum and cholera morbus were terms 
for non- specific diarrhea or dysentery in children and adults, respectively. Cholera 
morbus was attributed to contaminated food, while cholera infantum caused the deaths of 
children under the age of five and was linked to teething and finger foods, for example, it 
was responsible for the deaths of many children in 19th century in Illinois (18). 
  
Cholera is an acute, diarrheal intestinal infection caused by the bacteria, V. 
cholerae. It is nicknamed the “blue death” because infected individual’s skin often turns 
bluish from sever loss of water and electrolytes. Among infected people who show 
symptoms, the majorities have minor to moderate symptoms, with a smaller number 
developing acute watery diarrhea with severe dehydration, which can prompt to death if 
left untreated. The classic symptoms usually begin between two hours to five days after 
exposure and are characterized by massive amounts of watery diarrhea that lasts for 
several days. Abdominal pain and cramps, vomiting of clear fluid, nausea, excessive 
sweating, and blue-tinged skin due to uncontrolled dehydration are other common 
symptoms. Diarrhea can be severe, leading to rapid dehydration and lose of electrolytes, 
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creating an imbalance. Infected individuals with cholera produce10–20 liters of rice-
water diarrhea per day. If no treatment is provided and diarrhea persists, infected 
individuals can die by the end of the first day. Fever is not common and should raise 
suspicion for secondary infections (19). 
2.2 Laboratory Diagnosis 
Routinely, a panel of laboratory tests is conducted to confirm that the causative 
agent of an infection is V. cholerae. The laboratory tests to diagnose cholera involve (i) 
using culture plates (the gold-standard method), (ii) molecular testing for V. cholerae O1 
and O139 strains using rapid immunochromatographic dipstick testing in endemic areas, 
and (iii) test for antibodies against V. cholerae using the enzyme-linked immunosorbent 
assay (ELISA) technique (20). 
 
2.2.1 Culture Method 
A stool sample is taken from an infected patient using a sterile cotton bud and 
placed on a special culture plate called a thiosulphate citrate bile salts (TCBS) agar, 
which is a selective medium plate used to isolate bacteria, especially V. cholerae, V. 
parahaemolyticus, and other Vibrio species, from diarrheal deposits. The TCBS agar 
contains high concentrations of sodium thiosulphate and sodium citrate to prevent the 
growth of Enterobacteriaceae, whereas bile salts and sodium cholate inhibits the growth 
of gram-positive bacteria. It also contains a fermentable sucrose to metabolize the Vibrio 
species. The medium has an alkaline pH to enhance growth of V. cholerae and inhibits 
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growth of intestinal flora. Other additives are indicators of pH changes, used to show the 
limits of colony growth, such as thymol blue and bromothymol blue. After applying the 
proper streaking on the agar using a cotton bud, the plate is placed in an aerobic incubator 
at 35ºC for 18–24 hours. Immediately after removal from the incubator, the plate is 
examined for characteristic yellow of V. cholerae colonies. Other Vibrio species may 
grow with different shades of green, yellow, or even blue, such as V. parahaemolyticus, 
V. fluvialis, and V. vulnificus (Table 2). Using the TCBS agar provides a definitive 
diagnosis because it distinguishes Vibrios from other bacteria, viruses, or protozoa that 
cause diarrhea (21). 
 
Table 2. Colonial morphology on a TCBS agar 
Vibrio Species Colonial Morphology 
V. cholerae Yellow colonies 
V. parahaemolyticus Blue- to green-centered colonies 
V. vulnificus Green (85%) or yellow (15%) 
V. hollisae Green (very poor growth) 
V. metschnikovii Yellow (low growth) 
V. mimicus, V. demsela Green colonies 
V. alginolyticus, V. fluvialis, V. furnissii Yellow colonies 
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2.2.2 Molecular Testing for O1 and O139 Strains 
Molecular assays are usually used as secondary diagnostic tests for V. cholerae 
detection. Polymerase chain reactions (PCRs) are the most well-known and well-
documented molecular procedure for detecting different DNA sequences of the O1 and 
O139 strains. PCRs can detect multiple genes, such as the regulatory ToxR (found in all 
V. cholerae species), tcpA genes of both classic and El Tor biotypes (to distinguish 
between them), the wbe gene sequence (specific to O1 and O139 antigens), and the 
CTXA gene that encodes the A subunit (21). 
 
2.2.3 Rapid Immunochromatographic Dipstick Testing 
Various rapid diagnostic immunochromatographic tests have been described to 
prove the presence of V. cholerae by detecting the cholera toxin or lipopolysaccharide 
(LPS) antigen found in the O1 or O139 strains. The most recently developed colorimetric 
immunoassay is the multistep Sensitive Membrane Antigen Rapid Test (SMART), which 
has a 95% sensitivity and 100% specificity for the O1 V. cholerae strain and 100% 
sensitivity and 97% specificity for the O139 strain. Stool samples should be collected 
through out the acute phase of the sickness, when pathogens are present in the highest 
numbers, prior to antibiotic therapy. A strip from the rapid dipstick laboratory kit can be 
placed in the stool for fast biochemical reactions to allow immediate Vibrio confirmation. 
Cholera is confirmed after 2–15 minutes, when two red lines appear on the dipstick; it 
should be ruled out if only one red line appears. The first red line is the control, whereas 
the second is coated with conjugated antibodies that are specific to V. cholerae antigens. 
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When the antibodies capture the antigens, the reddish purple line starts to develop. 
Patient samples can be stored in cases for which repeating the test is necessary (22). 
 
2.2.4 Testing for Antibodies Against V. Cholerae Using an Enzyme-Linked 
Immunosorbent Assay 
GM1 ganglioside is the natural receptor for the cholera toxin in the small intestine 
of humans; thus, a ganglioside enzyme-linked immunosorbent assay (GM1-ELISA) was 
developed to detect this. To perform this test, several colonies from the TCBS agar are 
diluted into distilled water to create culture supernatants, which are added to microtiter 
plate wells coated with GM1 ganglioside. With time, cholera toxin will bind to the GM1 
receptors to form a complex that can be detected by adding antiserum, followed by the 
enzyme-conjugated antiglobulin antibody. The well is then inserted in the ELISA 
machine to measure antibody titer in each well (23). 
 
2.3 Pathogenesis  
  Evolution and emerging bacterial pathogens from new strains depend on 
horizontal and vertical transfer of virulence genes by phage, plasmids, chromosomal 
(pathogenicity) islands, transposons, and other genetic elements through the bacterial 
population, allowing excess evolutionary fitness for pathogenic host cells and, therefor, to 
associated nucleic acids. Now and again, these components can be manipulated to study 
transmissions between strains in well-constructed laboratory environment, but little is 
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thought about the conditions required to excite genetic exchange between clones and 
strains.  
 
V. cholerae transmitted through the fecal–oral route is responsible for a spectrum 
of clinical manifestations and a range of disease severity from asymptomatic to lethal. 
Most infected individuals who do not show symptoms still harbor the bacteria, which are 
found in their feces for 1–10 days post-infection. These bacteria are shed into the 
environment until they infect other individuals. Most cholera cases involve acute diarrhea 
that sometimes progresses to dehydration resulting in death within hours, which is known 
as “cholera gravis” or fatal diarrhea. Usually, the bacteria are sensitive to gastric acid and 
most die in the stomach, but some of the surviving virulent organisms may adhere to the 
small bowel and multiply (24). While colonizing, they secrete potent cholera enterotoxin 
(also called “choleragen”) that binds to the plasma membranes of intestinal epithelial 
cells and releases enzymatically super-active subunits responsible for over production of 
cyclic adenosine 51-monophosphate (cAMP).  
 
The B subunit (CTB) of the toxin targets GM1 gangliosides and binds to the 
intestinal surface and other types of glycans to facilitate toxin entrance. GM1 contains a 
pentasaccharide moiety with two galactose residues: N-acetyl galactose (GalNAc) and 
glucose (Glc) and N-acetylneuraminic acid (NANA; Figure 7). The toxin complex is 
ready to seize endogenous pathways of the host cell once it has been endocytosed (the 
active-transport process) by the cell; then, the A subunit is activated by the hemagglutinin 
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metalloprotease (HA Protease) into CTA1 and CTA2 chains that are linked by a single 
disulfide bond. The CTA1 peptide chain is released and recognized by the endoplasmic 
reticulum chaperon before it begins to unfolding. Then, CTA1 leaves the endoplasmic 
reticulum through the Sec61 channel to the cytoplasm, where it refolds and evades 
deactivation as a result of ubiquitination. The CTA1 chain is now free in the cytoplasm to 
bind to host proteins, called ADP-ribosylation factor 6 (Arf6). This changes the shape of 
CTA1 to enable catalytic activity. Subsequently, adenylate cyclase is increased and 
stimulates the production of cAMP to more than 100-folds the normal rate. The increased 
intracellular cAMP phosphorylates the cystic fibrosis transmembrane conductance 
regulator (CFTR) chloride channel proteins, which lead up to these constantly opening 
and the efflux of chloride ions, resulting in massive secretion of H2O and electrolytes 
(Na+, K+, and HCO3) into the lumen. This creates the characteristic watery diarrhea of 
cholera (Figure 8) (25). 	  
	 21	
 
 
Figure 7. Structure of the membrane glycolipid GM1, which composed of a pentasaccharide 
moiety [Gal(β1-3)GalNac(β1-4)(NeuAc(α2-3)Gal(β1-4)Glc(β1-1)] uncovered at the surface of 
the cell membrane and tightly anchored by a ceramide tail. The ceramide endings are embedded 
into the external leaflet of the plasma membrane (17). 
	 22	
 
Figure 8. A working model for trafficking cholera toxin into intestinal epithelial cells. Cholera 
toxin subunit B binds to the GM1 receptor. After endocytosis, the CT-GM1 complex 
retrotranslocates through the Golgi apparatus into the lumen of the endoplasmic reticulum 
(ER), where the A subunit detaches from the B subunit and the A1 peptide chain activates the 
ER Associated Degradation pathway (ERAD). A1 released into the lumen of the ER through the 
sec16 translocon before entering the cytosol. The B subunit doesn’t get unfold in the ER and 
proceed to the basolateral membrane by trafficking back out of the secretory pathway (15). 
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2.4 Treatment 
Dehydration can lead to death if fluid loss is more than one liter per hour, unless 
promptly treated by aggressive fluid repletion and electrolyte replacement therapy to 
restore hydration. Severe cases may require intravenous fluid replacement therapy. 
Cholera therapy also includes oral administration of a cholera vaccine consisting of dead 
V. cholerae. The risk of contracting the disease varies from one area to another based on 
precautions that are taken. To avoid infection, residents and visitors to an infected area 
should always drink bottled, boiled, or chemically-treated water with unbroken seals and 
never drink directly from tap water or a fountain. Boiling is a widely used procedure to 
disinfect water in endemic areas. Even dishes should be washed with hot, chemically 
treated water or 60% alcohol-based hand cleaner, if water is not available (19). Only 
packaged food or freshly cooked food should be consumed and raw or undercooked 
meats, unpeeled fruits and vegetables, and undercooked seafood should be avoided. 
Sewer systems must be established in endemic areas, following proper standards for feces 
disposal in a sanitary manner and defecation should never occur in a natural water source 
to prevent contamination of both water and food. Visitors can use chemoprophylaxis 
along with antibodies to lower their chances of contracting cholera (27). 
2.4.1 Vaccines 
Since the discovery of cholera in the nineteenth century, researches have sought 
to perfect a vaccine. Different types of vaccines have been developed, such as oral 
cholera vaccines (OCVs) and parenteral vaccines. OCVs are efficient methods of 
stimulate intestinal mucosal immune responses to produce antibodies against V. cholerae. 
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In comparison to parenteral delivered vaccines, oral vaccines have low risk for 
blood-transmitted diseases, are easier to administer, and are more convenient for patients 
(28). There are two types of OCVs: killed whole-cell (WC) and live attenuated vaccines. 
The killed WC vaccines include killed cholera cells from both the El Tor and classical 
biotypes, the Ogawa and Inaba serotypes of the O1, and the recombinant B subunit toxin. 
These vaccines are suitable for individuals who are two years old or more and are 
administered through multiple doses (i.e., two doses for both children (more than 6 years 
old) and adults and three doses for children less than 5 years old) (29). There are four 
main OCVs with different trade names that target different biotypes (Table 3) (20).  
 
Table 3. Licensed Oral Cholera Vaccines (20) 
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2.5 Government Efforts  
Assistance is provided to affected countries from various international agencies. 
Public health authorities have always put massive efforts into enhancing surveillance for 
cholera outbreaks by investigating every cholera-like case across the globe (27). The 
Center for Disease Control and Prevention (CDC) monitors these cases, keeps accurate 
records of the affected countries, and encourages the continuous training of laboratory 
workers to ensure professional identification techniques for V. cholerae are used. The 
CDC also provides informative materials about cholera diagnosis and treatment to 
educate the public about how to reduce the chances of contracting the disease. For 
example, the US agency for International Development provides medicine and medical 
supplies, bottled water, and sanitation supplies, such as cleaning detergents and hand 
sanitizers to affected areas. The Food and Drug Administration tests locally caught and 
imported sea animals, such as shellfish, for V. cholerae based on the “Shellfish Sanitation 
Program”. Haiti is at the top of the list of countries associated with the epidemic and 
recently suffered from an outbreak of V. cholerae in its capital city and villages along the 
Artibonite River. The Haitian Ministry of Public Health and Population (MSPP) 
immediately notified the National Public Health Laboratory, which identified the 
causative bacteria as V. cholerae serogroup O1, serotype Ogawa. The MSPP, with the 
help of governmental and nongovernmental partners, established a preventive protocol to 
(i) provide better water sources and access to drink water, (ii) educate residents on the 
proper food preparation practices, (iii) advise patients to start rehydration at the onset of 
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the watery diarrhea, (iv) and increase the number of healthcare institutions and their 
capacity to treat as many patients as possible (30). 
 
3. ABO BLOOD GROUPS 
3.1 History 
          The first blood transfusion in history was applied by Richard Lower, a member of 
the Royal Society (a prestigious scientists’ organization) in 1665 on animals (31). His 
first experiment was a blood transfusion from a mastiff (a large breed of dog) to an 
injured medium-size dog. Lower’s noticed that the recipient dog regained wellness and 
did not develop any signs of discomfort. After this experiment, he transfused animal 
blood to humans, but the recipients were not affected, even though animals’ blood was 
incompatible with the humans’, because he only transfused small amounts. In 1668, the 
Royal Society prohibited practicing blood transfusion to prevent unpredictable 
consequences (32). 
3.2 Blood Groups Discovery 
Karl Landsteiner discovered the principle of blood types in 1900 at the University 
of Vienna while attempting to understand why some blood transfusions saved patients 
and others caused death (31). His work was influenced by Paul Ehrlich’s article about 
goats’ blood typing that was published in 1900 (31). In 1901, Landsteiner discovered 
blood types A, B, and O, which he called A, B, and C (Figure 9). Two scientists working 
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under Landsteiner, Adriano Sturli and Alfred von Decastello, discovered the AB blood 
type a year later. Landsteiner received the Nobel Prize for his discovery in 1930 (32). 
 
 
Figure 9. Blood types and their surface antigens, from left to right: blood group A has antigen A 
on its surface, blood group B has antigen B on its surface, blood group AB has both antigens A 
and B on its surface, blood group O has no antigens on its surface. 
 
3.3 Blood Groups and Susceptibility to Infections  
Many studies have focused on the possible relationship between blood type and 
infections (33). This field of interest deals with four main aspects: the antigenic 
relatedness and similarities of microbe and erythrocytes membranes, adhesion to cells 
through specific receptors or blood group substances, modulation of the antibody 
response, and anthropologic surveys that link the geographic and racial variables among 
humans to blood type susceptibility to infectious diseases (Tables 4-6) (33). 
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Table 4. Associations between human blood type and bacterial infections (33) 
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Table 5. Associations between human blood type and viral infections (33) 
 
 
 
Table 6: Associations between human blood types and parasitical infestations (33) 
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4. PUBLISHED STUDIES 
4.1 Correlations between Blood Type and V. Cholerae 
 
In 1977, Barua and Paguio suggested an association between ABO blood groups 
and cholera infection after examining a group of patients presenting with diarrheal illness 
and taking the cholera treatment at San Lazaro Hospital. Among these patients, the 
severity of the disease varied even though they were infected with the same V. cholerae 
serotype. After further investigation, the patients were found to be of blood group O, 
which was associated with their more severe symptoms compared to other patients. 
 
Infection with cholera is associated with different factors, such as immunity, 
gastric acidity, bacterial inoculum size, and blood group. Different blood groups have 
different surface proteins. The surface proteins on red blood cells of an individual 
determine the blood type or group and are known as antigens. These antigens are not 
restricted to red blood cells; they are also present on tissues, which are referred to as 
histo-blood-group antigens. Individuals in blood group O are more vulnerable to cholera 
infection compared to individuals with different blood types, but the mechanism of this 
vulnerability is not fully understood. Type O red blood cells have no proteins (antigens) 
on their surface, in contrast to blood types A, B, or AB. After drinking contaminated 
water (or consuming contaminated undercooked food), colonization, and secretion of 
cholera toxin, the B subunit of the V. cholerae toxin binds to the small intestine epithelial 
cells’ receptor GM1, followed by penetration of host cells by the A subunit, which 
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interrupts the cAMP pathway. For individuals with blood types other than the O, surface 
proteins distract the B subunit of the cholera toxin and reduce its chances of binding to 
the GM1, thus reducing the severity of infection. Because blood type O erythrocytes lack 
these surface proteins, they cannot serve as distractions; thus, they cannot interfere with 
the B subunit binding to the GM1, which eventually leads to severe diarrheal illness   
(34-37). 	
 
4.2 Blood Group O Individuals Are More Susceptible to Cholera 
  
 The human body naturally secretes antibacterial and antitoxic antibodies, 
which work together cooperatively to defend the host against V. cholerae. Various types 
of oral vaccines have been developed to support the body’s natural defense mechanisms 
(40). In one study in Bangladesh, a group of scientists constructed a cohort study 
proposing a speculation for understanding the relationship between blood type O and the 
risk of contracting V. cholerae O1 and O139 along with developing severe illness. They 
enrolled 300 patients and 912 household contacts between 2001 and 2004. Of these, only 
269 patients and 793 contacts completed the required day of follow-up (21 days) and 
were included in their analysis (40). They included the statistic, microbiologic, clinical, 
and immunologic characteristics of both patients and household contacts (Table 7). 34% 
of the patients and 33% of the households were blood type O. They found; fifty-seven 
(21%) of the afflicted persons with V. cholerae O139, while 212 (79%) were infected 
with O1 El Tor biotype (83 were infected with Ogawa serotype and 129 with Inaba 
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serotype). More that 90% of patients had massive dehydration and were given 
intravenous fluid and antibiotics. They gave vibriocidal to both patients and household 
contacts and the results were; patients with blood type O had higher vibriocidal titers on 
the 21-day of follow-up after the onset of symptoms than those with different blood types 
(Figure 10). Of the household contacts, individuals with blood type O had much more 
severe symptoms comparing to persons with other blood types     (Table 8) (40). 
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Table 7. Statistic, microbiologic, clinical, and immunologic components of cholera 
patients and their household contacts (40) 
 
Characteristic Patients 
(N=269) 
Household contacts 
Infected (N=260) Not Infected 
(N= 533) 
P (for infected 
versus uninfected 
household 
contacts) 
Demographic data 
Age 
Female 
 
25 (±14) 18 (±15) 21 (±15) 0.03 
155 (58%) 132 (51%) 267 (50%) 0.8 
Blood group 
    O 
    A 
    B 
    AB 
 
115 (43%) 74 (28%) 190 (36%) 0.03 
60 (22%) 67 (26%) 136 (26%) 0.9 
72 (27%) 85 (33%) 155 (29%) 0.4 
22 (8%) 34 (13%) 52 (10%) 0.1 
Stool or rectal swab 
culture result 
    Any 
    O1 Inaba 
    O1 Ogawa 
    O139 
 
269 (100%) 185 (72%) NA  
129 (48%) 83 (32%) NA  
83 (31%) 53 (20%) NA  
57 (21%) 49 (19%) NA  
Severe dehydration 241 (90%) 0 (0%) NA  
Immunologic data 
     
Baseline log10 
vibriocidal antibody titer 
 
Day 21 log10 vibriocidal 
antibody titer 
 
Baseline log10 anti-CT 
IgG 
Day 21 log10 anti-CT 
IgG 
Fourfold rise in 
vibriocidal antibody titer 
 
1.8 (±0.7) 1.6 (±0.9) 1.9 (±0.9) 0.001 
3.3 (±0.6) 2.6 (±0.9) 1.9 (±0.9) <0.001 
2.0 (±0.3) 1.9 (±0.3) 2.0 (±0.4) 0.5 
2.4 (±2.4) 2.2 (±0.3) 2.0 (±0.3) <0.001 
265 (99%) 190 (73%) NA  
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Figure 10. Vibriocidal counter acting agent reactions in patients with cholera by blood 
aggregate. P values allude to the distinctions in mean titer between blood group O and non-
blood group O patients on days 2, 7, and 21 (40). 
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Table 8. Danger of disease and serious loose bowels on both patients and households 
with Vibrio cholerae O1 and O139 infection (40) 
 
V. 
cholerae 
serogroup 
in index 
patient 
Blood 
group of 
household 
contact 
Infection 
in 
household 
contact 
OR for 
infection 
(95% CI) 
P 
Severe 
diarrhea 
in 
household 
contact, if 
infected 
OR for 
severe 
diarrhea 
(95% CI) 
P 
O1 & 
O139 
combined 
O 74/264 
(28%) 
0.80 
(0.65-
0.98) 
0.03 14/66 
(21%) 
2.4 (1.2-4.7) 0.01 
Non-O 186/529 
(35%) 
 15/173 
(9%) 
 
O1 O 49/208 
(24%) 
0.67 
(0.53-
0.85) 
0.0008 8/43 (19%) 2.3 (0.98-5.6) 0.055 
Non-O 151/423 
(36%) 
 11/139 
(8%) 
 
O139 O 25/56  
(45%) 
1.2 (0.80-
1.9) 
0.32 6/23 (26%) 2.3 (0.86-6.2) 0.10 
Non-O 35/106 
(33%) 
 4/34 (12%)  
 
To further study the association between blood groups and the severity of cholera, 
Clemens and colleagues performed a study in Bangladesh to study the risk of severe 
cholera, blood group type, and the efficiency of oral vaccination (25). They randomly 
selected patients of different ages to take three doses of either cholera B subunit-whole 
killed vaccine (BS-WC), whole-killed cell only vaccine (WC), or an Escherichia coli K12 
strain placebo (K12). They had 3,647 patients who finished the three-doses trial of 895 
(24.5%) with blood type A, 1,247 (34.2%) with blood type B, 324 (8.9%) with blood type 
AB, and 1.181 (32.4%) with blood type O. They found that the risk to El Tor cholera 
among blood type O is markedly significant than the risk from groups A, B, and AB 
combined in children (Table 9) (25). 
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Table 9. Placebo Observation of El Tor (25) 
 
Feature No. of cholera patients in blood group (risk per thousand) 
AB A B O 
Age (in years)* 
2-5a 
>5 
 
0 4 (4.3) 4 (3.1) 21 (16.9) 
2 (1.3) 12 (2.9) 14 (2.4) 21 (3.8) 
Severity 
Severeb 
Nonseverec 
 
1 (0.5) 13 (2.5) 8 (1.1) 27 (4.0) 
1 (0.5) 3 (0.6) 10 (1.4) 15 (2.2) 
 
* At introductory vaccination in January 1985. 
a P < .005 (two-tailed) for pattern of increasing risk for groups AB, A and B combined, and O; 
and P < .0001 (two-tailed) for difference of risk between group O and other ABO groups. 
b P < 005 (two-tailed) for pattern of increasing risk for groups AB, A and B combined, and O; and  
  P < .001 (two-tailed) for difference of risk between group O and other ABO groups. 
c P < .05 (two-tailed) for pattern of increasing risk for groups AB, A and B combined, and O, and  
  P < .01 (two-tailed) for difference of risk between group O and other ABO groups. 
 
 
The three medications had almost indistinguishable dispersions among members. 
Protective efficacy was 60% for BS-WK, and 55% for WC vaccine. Concluding that the 
protective efficacy against every single treated scene of cholera was lower among blood 
group O people and indicated low level of protection against El Tor than other blood 
types (Table 10). Their data confirmed that persons with blood group O are at higher 
hazard for El Tor cholera than other ABO blood groups individuals (25). 
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Table 10. Protection efficacy (PE) for the three medications among various blood 
classifications (25) 
 
Outcome No. of cholera episodes per treatment group (% 
Protective Efficacy) 
BS-WC WC K12 
Severe 
Group O 
All other groups 
Total 
   
31 (40)*a 28 (46)d 52 
20 (76)b 31 (63) b 84 
51 (62) b 59 (56) b 136 
Nonsevere 
Group O 
All other groups 
Total 
   
9 (72)c 16 (50)* 32 
22 (45)* 19 (52) d 40 
31 (57) b 35 (51) c 72 
Overall 
Group O 
All other groups 
Total 
   
40 (52) b 44 (47) c 84 
42 (66) b 50 (59) b 124 
82(60) b 94 (55) b 208 
* P < .05 (one-tailed) for PE 
a P < .01 (two-tailed) for difference of PE for group O versus other beneficiaries of BS_WC 
b P < .0001 (one-tailed) for PE 
c P < .001 (one-tailed) for PE 
d P < .01 (one-tailed) for PE 
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In a recent study, Kuhlmann and colleagues hypothesized that binding of cholera 
toxin to the gastrointestinal glycans of A, B, or AB blood groups may impede interaction 
of the toxin with GM1 receptors (31). To explore the immediate effect of blood group 
expression on cholera toxin activation of target cells, they picked a novel enteric model 
framework. First, they analyzed the capacity of toxin to activate cAMP in enteroids 
extracted from gastrointestinal stem cells acquired from persons with blood group O or 
blood group A. They found that enteroids summarize many characteristics of human 
intestinal epithelium, and erythrocytes are one of them. In addition, they express antigens 
of blood group on erythrocytes surface (Figure 11) (31).  
 
 
Figure 11. Immunofluorescence pictures of the developed enteroids exhibiting the presence of 
blood group O antigen H in enteroids extracted from blood group O persons (top), or blood 
group A persons (bottom) (Kuhlmann study; 31). 
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Therefore, they utilized enteroids isolated from ileal and colonic biopsies 
extracted from different people of different blood type to study CT-mediated initiation of 
cAMP. Strangely, intestinal cells of blood group O persons showed reliably elevation in 
cAMP levels comparing to cells of blood group A individuals (Figure 12) (31). 
 
 
Figure 12. cAMP production results after a overnight incubation of ileal enteroids with cholera 
(CT, 0.1 µg/mL). Data of both blood groups from two distinct subjects (Kuhlmann study; 31). 
 
 
Despite the fact that cholera is thought to be an ileal infection, they found that 
colonic biopsies cells from blood group O persons showed more strong cAMP reaction 
when exposed to cholera toxin (Figure 13) (31). 
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Figure 13. cAMP production results after a overnight incubation of colonic enteroids from both 
blood groups A and blood group O subjects (31). 
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DISCUSSION 
 
Despite numerous studies having been conducted, the study of disease 
transmission and biology of cholera stay testing to explore because scientists cannot 
always determine its origin and where to begin investigation. Cholera remains a global 
health challenge, especially in developing countries in different parts of Asia and Africa. 
Recent efforts in this field have provided a motive for further investigation of the life 
form to comprehend the molecular basis for the rise of the sickness and natural marvels 
controlling the preservation of some hereditary attributes. V. cholerae gives a 
characteristic framework to concentrate the coevolution of microscopic organisms and 
the hereditary materials related with its virulence variables. 
 
Earlier research (28-30, 35, and 38) has pointed out that persons with blood group 
O are at risk for more severe symptoms due to higher concentrations of free toxin being 
available to bind GM1 on small intestinal epithelial cells, compared to other blood 
groups. It has been suggested (31) that blood types A and B secrete substances that 
reduce antibodies and cross-react with the cholera toxin. Blood types other than O may 
be able to change intestinal microflora in a way that affects V. cholerae multiplication 
and binding (41). Toxigenic serogroups O1 and O139 of V. cholerae are responsible for 
worldwide epidemics, whereas non-O1 and non-O139 serogroups cause occasional 
diarrhea or irregular extra-intestinal infections. So far, the World Health Organization 
supports administration of the whole-killed cholera vaccine WC-rBS to protect against  
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V. cholerae O1 classical and El Tor and control epidemics (39). The vaccines elevate 
serum antibodies in all recipients, whether they receive the whole Vibrio alone or 
combined with genetically recombinant B subunits. Additionally, half of the individuals 
who receive the combination vaccine show significant increases in IgA antibodies, even 
though the mechanisms of protective immunity are still not fully understood. 
   															New approaches are needed to help design the most effective vaccine or drugs to 
inhibit the binding process of the V. cholerae toxin to the GM1 ganglioside presented on 
the intestinal squamous cells. Computational biology and phage therapy are options to 
help for future therapies. Phage therapy involves the targeted application of 
bacteriophages that can infect and kill them and could be used as a prophylaxis to prevent 
the spread of cholera and sometimes cures the infection. 
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